Abstract 3149: Micronuclei (MN) dynamics in preclinical models and in patient reticulocytes as a pharmacodynamic biomarker for the first in class DNA polymerase theta (PolΘ) inhibitor ART6043
Colette L Baxter(Pharma Nord (United Kingdom)), Graeme C. Smith(Pharma Nord (United Kingdom)), Paula Costales(Pharma Nord (United Kingdom)), Minal Barve(Mary Crowley Cancer Research Center), Dorothea K. Torous(Litron Laboratories (United States)), Jeff Bemis(Litron Laboratories (United States)), Sarah V. Holt(Pharma Nord (United Kingdom)), Jayesh B. Majithiya, Susanna V. Ulahannan(Oklahoma State University Oklahoma City), Helen M. Robinson(The University of Melbourne), Babar Bashir(Thomas Jefferson University), Svetlana L. Avlasevich(Litron Laboratories (United States)), Gillian Langford(Pharma Nord (United Kingdom)), Marina Roy-Luzarraga(Pharma Nord (United Kingdom)), Bryony Harrop(Pharma Nord (United Kingdom)), Susana Barriga(Pharma Nord (United Kingdom)), Ian Smith(Pharma Nord (United Kingdom)), Samantha C. Skelton(Pharma Nord (United Kingdom)), Erika Hamilton(Sarah Cannon), Timothy A. Yap(The University of Texas MD Anderson Cancer Center), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics)
Cited by 0
Related Papers
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Targeting HER2-positive breast cancer: advances and future directions
|Nature Reviews Drug Discovery|2022|1k
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
HER2-Low Breast Cancer: Pathological and Clinical Landscape
|Journal of Clinical Oncology|2020|801
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766